Cargando…

FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model

Disclosure: H. Choe: None. Y. Ko: None. S. Moon: None. C.H. Ahn: None. K. Ha: None. H. Lee: None. J. Bae: None. H. Joo: None. H. Lee: None. J. Sohn: None. D. Kim: None. S. Kim: None. K. Kim: None. Y. Cho: None. Objective: To estimate the economic benefit of replacing non-renal dose adjusted (NRDA) d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jee Choe, Hun, Ko, Yeh-Hee, Joon Moon, Sun, Ahn, Chang H, Hwa Ha, Kyoung, Lee, Hyeongsuk, Hyun Bae, Jae, Joon Joo, Hyung, Lee, Hyejin, Sohn, Jang-Wook, Kim, Dae-Jung, Gon Kim, Sin, Kim, Kwangsoo, Min Cho, Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553634/
http://dx.doi.org/10.1210/jendso/bvad114.853
_version_ 1785116218334642176
author Jee Choe, Hun
Ko, Yeh-Hee
Joon Moon, Sun
Ahn, Chang H
Hwa Ha, Kyoung
Lee, Hyeongsuk
Hyun Bae, Jae
Joon Joo, Hyung
Lee, Hyejin
Sohn, Jang-Wook
Kim, Dae-Jung
Gon Kim, Sin
Kim, Kwangsoo
Min Cho, Young
author_facet Jee Choe, Hun
Ko, Yeh-Hee
Joon Moon, Sun
Ahn, Chang H
Hwa Ha, Kyoung
Lee, Hyeongsuk
Hyun Bae, Jae
Joon Joo, Hyung
Lee, Hyejin
Sohn, Jang-Wook
Kim, Dae-Jung
Gon Kim, Sin
Kim, Kwangsoo
Min Cho, Young
author_sort Jee Choe, Hun
collection PubMed
description Disclosure: H. Choe: None. Y. Ko: None. S. Moon: None. C.H. Ahn: None. K. Ha: None. H. Lee: None. J. Bae: None. H. Joo: None. H. Lee: None. J. Sohn: None. D. Kim: None. S. Kim: None. K. Kim: None. Y. Cho: None. Objective: To estimate the economic benefit of replacing non-renal dose adjusted (NRDA) dipeptidyl peptidase-4 (DPP4) inhibitors with renal dose adjusted (RDA) DPP4 inhibitors in patients with impaired kidney function and type 2 diabetes. Patients and Methods: This multicenter study analyzed a total of 67,964,996 prescription records of five teaching hospitals in Korea from January 1, 2012 to December 31, 2018 using a common data model. Prescription patterns of NRDA and RDA DPP4 inhibitors were subgrouped based on estimated glomerular filtration rate (eGFR) determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Results: NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than those with preserved kidney function (25.7%, 51.3%, 64.3%, and 71.6% in patients with eGFR of ≥60, <60, <45, and <30 mL/min/1.73m(2), respectively). When applying the prescription pattern of DPP4 inhibitors for patients with preserved kidney function to those with impaired kidney function, cost savings per year were 7.6% for eGFR <60 mL/min/1.73m(2) and 30.4% for eGFR <30 mL/min/1.73m(2). Assuming patients with impaired kidney function are solely prescribed with RDA DPP4 inhibitors with appropriate dose reduction, 15.4% to 51.2% per year could be saved depending on kidney impairment severity. Conclusion: NRDA DPP4 inhibitors are frequently prescribed in patients with type 2 diabetes and CKD. Prescribing RDA DPP4 inhibitors with doses adjusted to individual kidney function could alleviate the economic burden associated with medical expenditure. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10553634
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105536342023-10-06 FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model Jee Choe, Hun Ko, Yeh-Hee Joon Moon, Sun Ahn, Chang H Hwa Ha, Kyoung Lee, Hyeongsuk Hyun Bae, Jae Joon Joo, Hyung Lee, Hyejin Sohn, Jang-Wook Kim, Dae-Jung Gon Kim, Sin Kim, Kwangsoo Min Cho, Young J Endocr Soc Diabetes And Glucose Metabolism Disclosure: H. Choe: None. Y. Ko: None. S. Moon: None. C.H. Ahn: None. K. Ha: None. H. Lee: None. J. Bae: None. H. Joo: None. H. Lee: None. J. Sohn: None. D. Kim: None. S. Kim: None. K. Kim: None. Y. Cho: None. Objective: To estimate the economic benefit of replacing non-renal dose adjusted (NRDA) dipeptidyl peptidase-4 (DPP4) inhibitors with renal dose adjusted (RDA) DPP4 inhibitors in patients with impaired kidney function and type 2 diabetes. Patients and Methods: This multicenter study analyzed a total of 67,964,996 prescription records of five teaching hospitals in Korea from January 1, 2012 to December 31, 2018 using a common data model. Prescription patterns of NRDA and RDA DPP4 inhibitors were subgrouped based on estimated glomerular filtration rate (eGFR) determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Results: NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than those with preserved kidney function (25.7%, 51.3%, 64.3%, and 71.6% in patients with eGFR of ≥60, <60, <45, and <30 mL/min/1.73m(2), respectively). When applying the prescription pattern of DPP4 inhibitors for patients with preserved kidney function to those with impaired kidney function, cost savings per year were 7.6% for eGFR <60 mL/min/1.73m(2) and 30.4% for eGFR <30 mL/min/1.73m(2). Assuming patients with impaired kidney function are solely prescribed with RDA DPP4 inhibitors with appropriate dose reduction, 15.4% to 51.2% per year could be saved depending on kidney impairment severity. Conclusion: NRDA DPP4 inhibitors are frequently prescribed in patients with type 2 diabetes and CKD. Prescribing RDA DPP4 inhibitors with doses adjusted to individual kidney function could alleviate the economic burden associated with medical expenditure. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10553634/ http://dx.doi.org/10.1210/jendso/bvad114.853 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diabetes And Glucose Metabolism
Jee Choe, Hun
Ko, Yeh-Hee
Joon Moon, Sun
Ahn, Chang H
Hwa Ha, Kyoung
Lee, Hyeongsuk
Hyun Bae, Jae
Joon Joo, Hyung
Lee, Hyejin
Sohn, Jang-Wook
Kim, Dae-Jung
Gon Kim, Sin
Kim, Kwangsoo
Min Cho, Young
FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
title FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
title_full FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
title_fullStr FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
title_full_unstemmed FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
title_short FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model
title_sort fri633 financial benefits of renal dose-adjusted dipeptidyl peptidase-4 inhibitors for patients with type 2 diabetes and chronic kidney disease: a multicenter study utilizing common data model
topic Diabetes And Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553634/
http://dx.doi.org/10.1210/jendso/bvad114.853
work_keys_str_mv AT jeechoehun fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT koyehhee fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT joonmoonsun fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT ahnchangh fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT hwahakyoung fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT leehyeongsuk fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT hyunbaejae fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT joonjoohyung fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT leehyejin fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT sohnjangwook fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT kimdaejung fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT gonkimsin fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT kimkwangsoo fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel
AT minchoyoung fri633financialbenefitsofrenaldoseadjusteddipeptidylpeptidase4inhibitorsforpatientswithtype2diabetesandchronickidneydiseaseamulticenterstudyutilizingcommondatamodel